Q BioMed, Inc.

Quantifiable MRI aims to pull objectively accurate measurements from a scan, so that changes hidden within the body can be charted over time. Q Bio aims to have people reconsider the possibilities of an MRI machine, with an advance in computing that could one day enable new uses for the diagnostic imaging hardware. MRIs have excelled at providing a snapshot of the inside of the body—especially for clinicians seeking the causes behind a condition, such as a stroke, trauma or cardiac disease. However, those findings have always been subject to interpretation: The machine takes the picture and the radiologist reads it. While the use of artificial intelligence has grown by leaps and bounds among its siblings in digital imaging, notably in analyzing X-ray and CT scans, algorithm development in MRI has been a tougher climb. A seemingly unknowable amount of factors and variables between different equipment, hospital settings, and how the machines are used have made picking out the true signals in the noise a difficult task. Q Bio hopes to clear things up by offering quantifiable MRI, where a single scan can provide an easy-to-read assessment of the entire body and its various tissues.  Dubbed tensor field mapping, the approach is designed to be reproducible across both patients and machines—allowing repeated scans of the same person to accurately chart out changes in the body over time, while facilitating more data generation to help build the foundation of future AI applications. “There are many studies that show you can put the same person in the same scanner and still get different results—different pictures come out of it depending on the patient’s breath hold, or the angle that the MRI tech took the picture, and then the radiologist’s interpretation comes from all that,” Q Bio chief operating officer Clarissa Shen said in an interview. “That's fine when you're doing it for acute diagnostic purposes and you just need a one-off,” Shen added. “Our goal in quantified imaging, and where tensor field mapping comes in, is that we want highly reproducible imaging data—whether you're looking at a patient today or tomorrow, or from one scanner to another—so that you can do longitudinal tracking, and get real measurements versus a subjectively read measurement.” “And when you’re talking about AI, you need highly reproducible, high-quality data to build those second- and third-generation models,” she said. “Because if you take the data that's out there today—and we've proven this and shown this—you get hallucinations very quickly.” According to the company, quantifiable MRI approaches have been sought after for more than a decade but were once seen as computationally impossible. Its tensor field mapping approach to cracking the code is built on years of advancements in chips and processing power, which allows the construction of a digital co-simulation alongside the scan. “We put everything in—all the imperfections of the machine that we know about, the parameters of the environment—everything goes into this model,” said Q Bio VP of radiomicsThomas Witzel. “I mean these matrices are absolutely huge, with millions of unknown parameters. So it’s basically a computer engineer’s nightmare.” Still, in future practice, completing a quantified scan could be possible with a 100-fold reduction in relative computational power—taking just minutes while relying on a single GPU, the company said. Q Bio plans to build tensor field mapping into its own, purpose-built MRI machine. Called the Mark I, the upcoming open-design, full-body system is slated to operate largely automatically at lower magnetic field strengths compared to hospital scanners, and will not require shielded rooms or specialized cooling hardware.  The goal is to provide a high-throughput and affordable approach to MRI that will lend itself to tracking changes over time, and support the company’s other work in building digital twin models—which also incorporate an individual’s DNA and biochemical analyses of blood and urine. Q Bio currently offers whole-body, benchmark-setting exams through its pilot site in Redwood City, California, priced at $3,495 a piece. With tensor field mapping MRI, the company aims to capture figures such as the percentage of fat throughout the body—or, for example, fat specifically within and around organs like the liver and heart, forming two important factors in cardiometabolic conditions. “We are very much working towards the long-term vision that this becomes a preventive screening option,” said Shen. “This is really about changing how we think about personal baselines in health, and establishing even a baseline for health… Because today we have a lot of acute disease definitions, but we don't have a lot of definitions for what a healthy baseline actually looks like.” In terms of taking this technology to the larger players in digital imaging, Shen said the company is open to partnerships but it would require deep knowledge, access and potentially modifications to the scanners’ hardware in order to build computing models that work. Even then, larger, traditional machines may not be accessible enough for what Q Bio has in mind. “We want to get to an endpoint where this is something not only for the people who otherwise like to spend a lot of money but something that can be applied on a population scale,” said Witzel.

Instant quantifiable data from MRI imaging enables unparalleled diagnostic benchmarking and insights PALO ALTO, Calif.--(BUSINESS WIRE)-- Q Bio Inc., an innovator in medical imaging technology, today announced the launch of Tensor Field Mapping (TFM), a new technology for Magnetic Resonance Imaging (MRI) that provides detailed insights into the human body that were previously unimaginable. Unlike traditional MRIs that provide qualitative data prone to machine or clinical variations, TFM delivers quantitative, harmonized imaging data that can be immediately accessed by AI to accelerate diagnostics. "For decades, MRI technology has been invaluable in diagnosing a wide range of medical conditions, yet it has been limited by its qualitative nature and the variability of the data," said Jeff Kaditz, Founder and CTO / CEO, Q Bio. "With the introduction of Tensor Field Mapping, we are taking a quantum leap forward, making multi-parametric quantification of tissues reproducible across machines, which is key to AI in MRI and personalized medicine." TFM is the result of extensive research and development by Q Bio's team of experts in medical imaging, physics, and computational science, and will make its debut in the company’s upcoming Mark I full body scanner. The technology provides quantifiable data lacking in traditional MRIs so that properties of tissues can be measured and benchmarked on an ongoing basis. This advancement is crucial for the accurate diagnosis and treatment of diseases by enabling consistent and reliable imaging data that can be shared, pooled and compared, regardless of machines and clinical settings. "Quantified MRIs have been anticipated for over 25 years, TFM has been the breakthrough that has made them the reality," said Thomas Witzel, VP of Imaging at Q Bio, who spearheaded the development. "By modeling the entire imaging process without idealizing assumptions about the hardware, we're not only enhancing the quality of MRI data but also paving the way for the development of new MRI equipment optimized for speed and patient comfort." Key capabilities of TFM include: A 100-fold reduction in computational power requiring only a single GPU; Imaging harmonization across hardware, software and clinical variations for sharing and knowledge pooling; Maxwell regularization which ensures accurate coil sensitivity modeling; Advanced field calibration and motion reconstruction techniques that enhance data accuracy and integrity. "Tensor Field Mapping is more than an innovative technology; it's a vision for the future of medical imaging where frequency, accuracy, and benchmarking with commodity radiomic data is possible," added Clarissa Shen, COO, Q Bio. "We look forward to sharing our collaborations with healthcare providers and researchers to bring the benefits of TFM to patients around the world." Q Bio Inc. is committed to advancing medical imaging technology and improving patient outcomes. In addition to TFM’s upcoming debut in the Mark I full body scanner, the company also plans to explore the applicability of other hardware options. With the launch of Tensor Field Mapping, the company is at the forefront of a new era in diagnostics and personalized medicine. ABOUT Q BIO INC. Founded in 2015 by serial entrepreneur Jeff Kaditz, Dr. Michael Snyder and Dr. Garry Choy, Q Bio gives you a deeper understanding of your body and how it’s changing, so you have more control over your health. Q Bio’s platform is a quantitative, clinically-relevant assessment of personal human health. We believe in making preventive health available to everyone so that treatable diseases no longer take lives. Investors include Andreessen Horowitz, Khosla Ventures, Founders Fund, Kaiser Foundation Hospitals and others. For more information, visit q.bio. View source version on businesswire.com: Contacts q.bio@consortpartners.com Source: Q Bio Inc. View this news release online at:

NEW YORK, June 23, 2023 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides an update to shareholders. Due to the capital constraints and costs associated with the audit process the Company was not able to file complete audited financials for 2022. We tried to maintain our listing on the OTC by filing an un-audited annual report for 2022 and Q1 2023 thereby providing as much public disclosure as possible. Unfortunately, this was not sufficient to maintain our OTC listing compliance resulting in being downgraded to the 'Expert Market'. The Expert Market is available only for unsolicited quotes, meaning broker-dealers may use the Expert Market to publish unsolicited quotes representing limit orders from sophisticated retail and institutional investors. Many microcap biotechs have been under market pressure and QBioMed is one of those that have a capital requirement that is challenging to service given its debt and current lack of resources. The Company is determined to find a solution for the benefit of all our stakeholders and are engaged with consultants and bankers to restructure the Company for funding and relisting or possible M&A with compatible listed entities that may be looking for the type of portfolio assets QBioMed has. We remain committed to finding a way to unleash shareholder value and will endeavor to update the market at an appropriate time. About Q BioMed Inc. Q BioMed Inc. is a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed provides these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need‏. Please visit and sign up for regular updates. Investor Relations Contact: Landon Capital Keith Pinder (404) 995-6671 [email protected] Forward-Looking Statements: This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law. Logo: SOURCE Q BioMed Inc.